<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="211645">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00331500</url>
  </required_header>
  <id_info>
    <org_study_id>C-04-60</org_study_id>
    <nct_id>NCT00331500</nct_id>
  </id_info>
  <brief_title>Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis</brief_title>
  <official_title>A Comparative Study of Olopatadine 0.2% Versus Vehicle in Patients With Seasonal Allergic Conjunctivitis or Rhinoconjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that Olopatadine 0.2% is superior to vehicle in
      the treatment of the signs and symptoms associated with allergic conjunctivitis or
      rhinoconjunctivitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double-Blind</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Daily signs and symptoms scores during the 14 days of peak pollen</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients with daily signs and symptoms scores of zero during the 14 days of peak pollen</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Allergic Conjunctivitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olopatadine 0.2%</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of seasonal allergic conjunctivitis or rhinoconjunctivitis, a positive grass
             antigen challenge reaction (skin test), and a positive response to grass in the
             Conjunctival Allergen Challenge (CAC) model

        Exclusion Criteria:

          -  Under 10 years of age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stella Robertson</last_name>
    <role>Study Director</role>
    <affiliation>Study Director</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alcon Research, Ltd.</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>https://www.ncbi.nlm.nih.gov/pubmed/23379201</citation>
  </results_reference>
  <verification_date>June 2008</verification_date>
  <lastchanged_date>November 17, 2016</lastchanged_date>
  <firstreceived_date>May 30, 2006</firstreceived_date>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Olopatadine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
